Patents by Inventor Paul W. N. Keeling

Paul W. N. Keeling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
    Patent number: 6855729
    Abstract: The present invention provides a method for treating fibromyalgia and/or chronic fatigue syndrome by administering an antagonist or partial agonist of 5HT1a receptors.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: February 15, 2005
    Inventors: Timothy G. Dinan, Paul W. N. Keeling
  • Diagnosis and treatment of a disorder of the gastrointestinal tract
    Patent number: 5403848
    Abstract: Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine) for the treatment of non-ulcerative dyspepsia (NUD), more particularly NUD which is characterized by dysfunction of central 5-HT 1A receptors. Dysfunction of the central 5-HT 1A receptors can be diagnosed by an azaspirodecanedione-induced prolactin response which is distinguishable from that observed in a subject with peptic ulcer disease and/or inflammatory bowel disease. A suitable azaspirodecanedione for inducing the prolactin response is buspirone.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: April 4, 1995
    Assignee: Earlow Limited
    Inventors: Timothy G. Dinan, Paul W. N. Keeling
  • Diagnosis and treatment of a disorder of the gastrointestinal tract
    Patent number: 5324738
    Abstract: Cyproheptadine (4-(5H-dibenzo[a,d] cyclohepten-5-ylidene)-1-methylpiperidine) for the treatment of non-ulcerative dyspepsia (NUD), more particularly NUD which is characterised by dysfunction of central 5-HT 1A receptors. Dysfunction of the central 5-HT 1A receptors can be diagnosed by an azaspirodecanedione-induced prolactin response which is distinguishable from that observed in a subject with peptic ulcer disease and/or inflammatory bowel disease. A suitable azaspirodecanedione for inducing the prolactin response is buspirone.
    Type: Grant
    Filed: September 18, 1990
    Date of Patent: June 28, 1994
    Assignee: Earlow Limited
    Inventors: Timothy G. Dinan, Paul W. N. Keeling